
Progyny (PGNY) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
332.9M
Gross Profit
79.0M
23.72%
Operating Income
24.4M
7.32%
Net Income
17.1M
5.14%
EPS (Diluted)
$0.19
Balance Sheet Metrics
Total Assets
730.3M
Total Liabilities
263.1M
Shareholders Equity
467.2M
Debt to Equity
0.56
Cash Flow Metrics
Operating Cash Flow
27.8M
Free Cash Flow
47.0M
Revenue & Profitability Trend
Progyny Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.2B | 1.1B | 786.9M | 500.6M | 344.9M |
Cost of Goods Sold | 913.9M | 849.8M | 619.6M | 388.5M | 274.8M |
Gross Profit | 253.4M | 238.8M | 167.3M | 112.1M | 70.1M |
Gross Margin % | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 185.9M | 176.6M | 144.0M | 79.8M | 61.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 185.9M | 176.6M | 144.0M | 79.8M | 61.7M |
Operating Income | 67.5M | 62.2M | 23.3M | 32.3M | 8.3M |
Operating Margin % | 5.8% | 5.7% | 3.0% | 6.5% | 2.4% |
Non-Operating Items | |||||
Interest Income | 15.7M | - | - | - | - |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | - | 5.2M | 286.0K | -366.0K | 210.0K |
Pre-tax Income | 83.2M | 70.7M | 24.4M | 32.4M | 8.7M |
Income Tax | 28.9M | 8.7M | -5.9M | -33.3M | -37.8M |
Effective Tax Rate % | 34.7% | 12.2% | -24.2% | -102.8% | -435.3% |
Net Income | 54.3M | 62.0M | 30.4M | 65.8M | 46.5M |
Net Margin % | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% |
Key Metrics | |||||
EBITDA | 70.6M | 64.5M | 24.9M | 33.6M | 10.3M |
EPS (Basic) | $0.59 | $0.65 | $0.33 | $0.74 | $0.54 |
EPS (Diluted) | $0.57 | $0.62 | $0.30 | $0.66 | $0.47 |
Basic Shares Outstanding | 91481995 | 95021175 | 92195068 | 89105562 | 85722670 |
Diluted Shares Outstanding | 91481995 | 95021175 | 92195068 | 89105562 | 85722670 |
Income Statement Trend
Progyny Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 162.3M | 97.3M | 120.1M | 91.4M | 70.3M |
Short-term Investments | 65.6M | 273.8M | 69.2M | 28.0M | 39.0M |
Accounts Receivable | 235.3M | 241.9M | 240.1M | 134.6M | 75.7M |
Inventory | - | - | - | - | - |
Other Current Assets | 9.4M | 27.5M | 4.5M | 4.6M | 5.3M |
Total Current Assets | 472.7M | 640.4M | 433.9M | 258.5M | 190.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 17.3M | 17.6M | 6.9M | 7.8M | 9.7M |
Goodwill | 32.4M | 23.8M | 23.9M | 24.4M | 25.0M |
Intangible Assets | 1.3M | - | 99.0K | 599.0K | 1.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 87.9M | 76.5M | 81.9M | 74.2M | 38.5M |
Total Non-Current Assets | 134.4M | 116.2M | 109.1M | 99.5M | 63.7M |
Total Assets | 607.1M | 756.6M | 543.0M | 358.1M | 253.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 95.1M | 125.4M | 109.3M | 61.4M | 43.5M |
Short-term Debt | 2.9M | 2.1M | 1.2M | 1.2M | 1.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 5.3M | 1.2M | 1.2M | 2.2M | 2.6M |
Total Current Liabilities | 168.6M | 186.0M | 159.5M | 98.8M | 77.8M |
Non-Current Liabilities | |||||
Long-term Debt | 16.4M | 17.2M | 6.5M | 7.4M | 8.3M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | 876.0K |
Total Non-Current Liabilities | 16.4M | 17.2M | 6.5M | 7.4M | 9.2M |
Total Liabilities | 185.0M | 203.2M | 166.0M | 106.2M | 87.0M |
Equity | |||||
Common Stock | 9.0K | 9.0K | 9.0K | 9.0K | 9.0K |
Retained Earnings | 144.3M | 90.0M | 27.9M | -2.4M | -68.2M |
Treasury Stock | 303.9M | 1.0M | 1.0M | 1.0M | 1.0M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 422.1M | 553.4M | 377.0M | 251.8M | 166.9M |
Key Metrics | |||||
Total Debt | 19.3M | 19.4M | 7.7M | 8.6M | 9.5M |
Working Capital | 304.1M | 454.5M | 274.3M | 159.7M | 112.4M |
Balance Sheet Composition
Progyny Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 54.3M | 62.0M | 30.4M | 65.8M | 46.5M |
Depreciation & Amortization | 3.2M | 2.3M | 1.6M | 1.3M | 1.9M |
Stock-Based Compensation | 128.1M | 122.6M | 100.7M | 33.7M | 12.8M |
Working Capital Changes | -39.7M | -4.9M | -72.7M | -54.1M | -9.7M |
Operating Cash Flow | 135.5M | 185.8M | 53.4M | 13.4M | 13.6M |
Investing Activities | |||||
Capital Expenditures | -5.4M | -3.6M | -3.2M | -2.1M | -1.0M |
Acquisitions | -5.3M | - | - | - | - |
Investment Purchases | -170.3M | -429.7M | -163.3M | -111.5M | -104.0M |
Investment Sales | 376.8M | 232.8M | 122.7M | 122.4M | 65.0M |
Investing Cash Flow | 195.8M | -200.5M | -43.9M | 8.8M | -40.0M |
Financing Activities | |||||
Share Repurchases | -300.3M | - | - | 0 | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | 0 | 0 |
Financing Cash Flow | -312.3M | -17.2M | -12.1M | -18.0M | -9.8M |
Free Cash Flow | 173.7M | 185.2M | 77.2M | 23.9M | 35.2M |
Net Change in Cash | 19.0M | -31.9M | -2.6M | 4.2M | -36.3M |
Cash Flow Trend
Progyny Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
38.54
Forward P/E
29.92
Price to Book
3.77
Price to Sales
1.57
PEG Ratio
3.47
Profitability Ratios
Profit Margin
4.28%
Operating Margin
7.32%
Return on Equity
10.94%
Return on Assets
6.57%
Financial Health
Current Ratio
2.70
Debt to Equity
5.56
Beta
1.32
Per Share Data
EPS (TTM)
$0.59
Book Value per Share
$6.04
Revenue per Share
$14.32
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
pgny | 2.0B | 38.54 | 3.77 | 10.94% | 4.28% | 5.56 |
UnitedHealth | 279.4B | 13.35 | 2.95 | 21.65% | 5.04% | 75.58 |
CVS Health | 87.0B | 19.11 | 1.12 | 5.88% | 1.18% | 106.67 |
Clover Health | 1.3B | -31.50 | 3.87 | -12.59% | -2.68% | 0.00 |
Cigna | 79.2B | 16.28 | 1.97 | 13.18% | 1.92% | 76.10 |
Elevance Health | 70.8B | 13.35 | 1.62 | 12.42% | 2.83% | 68.84 |
Financial data is updated regularly. All figures are in the company's reporting currency.